Brogueira Rodrigues, F;
Byrne, L;
Lowe, A;
Tortelli, R;
Heins, M;
Flik, G;
Johnson, E;
... Wild, E; + view all
(2021)
Kynurenine pathway metabolites in cerebrospinal fluid and blood as potential biomarkers in Huntington’s disease.
Journal of Neurochemistry
10.1111/jnc.15360.
(In press).
Preview |
Text
Brogueira Rodrigues_jnc.15360.pdf - Published Version Download (1MB) | Preview |
Abstract
Converging lines of evidence from several models, and post‐mortem human brain tissue studies, support the involvement of the kynurenine pathway (KP) in Huntington's disease (HD) pathogenesis. Quantifying KP metabolites in HD biofluids is desirable, both to study pathobiology and as a potential source of biomarkers to quantify pathway dysfunction and evaluate the biochemical impact of therapeutic interventions targeting its components. In a prospective single‐site controlled cohort study with standardised collection of cerebrospinal fluid (CSF), blood, phenotypic and imaging data, we used high‐performance liquid‐chromatography to measure the levels of KP metabolites—tryptophan, kynurenine, kynurenic acid, 3‐hydroxykynurenine, anthranilic acid and quinolinic acid—in CSF and plasma of 80 participants (20 healthy controls, 20 premanifest HD and 40 manifest HD). We investigated short‐term stability, intergroup differences, associations with clinical and imaging measures and derived sample‐size calculation for future studies. Overall, KP metabolites in CSF and plasma were stable over 6 weeks, displayed no significant group differences and were not associated with clinical or imaging measures. We conclude that the studied metabolites are readily and reliably quantifiable in both biofluids in controls and HD gene expansion carriers. However, we found little evidence to support a substantial derangement of the KP in HD, at least to the extent that it is reflected by the levels of the metabolites in patient‐derived biofluids.
| Type: | Article |
|---|---|
| Title: | Kynurenine pathway metabolites in cerebrospinal fluid and blood as potential biomarkers in Huntington’s disease |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1111/jnc.15360 |
| Publisher version: | http://doi.org/10.1111/jnc.15360 |
| Language: | English |
| Additional information: | This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
| Keywords: | biomarkers, blood, cerebrospinal fluid, cohort studies, Huntington's disease, Kynurenine |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Neurodegenerative Diseases |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10125109 |
Archive Staff Only
 |
View Item |
